Long-Term Safety and Persistence of Effectiveness of Manualized MDMA Assisted Therapy for the Treatment of Posttraumatic Stress Disorder

This therapeutic exploratory trial (n=30, withdrawn), sponsored by MAPS Europe B.V., Netherlands, aimed to assess the long-term safety and persistence of effectiveness of manualized MDMA-assisted therapy for the treatment of posttraumatic stress disorder (PTSD).

Unfortunately, the trial was prematurely ended. It involved 30 adult participants, aged 18-64 years, and 7 elderly participants, aged 65 years and above, all diagnosed with PTSD. The trial did not involve any controlled or randomised aspects, being a long-term follow-up study with no investigational medicinal product given.

The main objective was to compare PTSD severity between groups who received MDMA versus Placebo during the parent study, based on assessments at Visit 1. The primary endpoint was the Clinician-Administered PTSD Scale for Diagnostic and Statistical Manual of Mental Disorders, 5th edition (CAPS-5) Total Severity Score, assessed at Visit 1. Secondary endpoints included the Sheehan Disability Scale for PTSD for MAPS Total score, also assessed at Visit 1.

The trial was conducted across six sites in the Czech Republic, Germany, Netherlands, Norway, and the United Kingdom. Unfortunately, the trial was prematurely ended, but prior to this decision, it had been authorised by the Competent Authority, with a favourable Ethics Committee Opinion.

Topic PTSD
Compound MDMA
Country Czech Republic Germany Netherlands Norway United Kingdom
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

MAPS
MAPS stands for Multidisciplinary Association for Psychedelic Studies, it's the front runner in making psychedelics a legal way to use (and improve) in therapy.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.